{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T22:33:14Z","timestamp":1794609194250,"version":"4.9.1"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40257-025-00997-x","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T07:14:05Z","timestamp":1764141245000},"page":"49-66","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Real-World Evidence of Effectiveness and Safety of Abrocitinib, Baricitinib and Upadacitinib in Atopic Dermatitis: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"27","author":[{"given":"Amalie Thorsti M\u00f8ller","family":"R\u00f8nnstad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Isufi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Bunick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Chovatiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia-Louise","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzad","family":"Alinaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon F.","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Vestergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Wollenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Egeberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob P.","family":"Thyssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2950-3280","authenticated-orcid":false,"given":"Nikolai","family":"Loft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"997_CR1","doi-asserted-by":"crossref","unstructured":"Bylund S, von Kobyletzki LB, Svalstedt M, Svensson \u00c5. Prevalence and incidence of atopic dermatitis: a systematic review. Acta Derm Venereol. 2020;100(12):320\u20139.","DOI":"10.2340\/00015555-3510"},{"issue":"2","key":"997_CR2","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/J.JAAD.2018.09.035","volume":"80","author":"YW Yew","year":"2019","unstructured":"Yew YW, Thyssen JP, Silverberg JI. A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics. J Am Acad Dermatol. 2019;80(2):390\u2013401. https:\/\/doi.org\/10.1016\/J.JAAD.2018.09.035.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"997_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/BJD\/LJAD401","volume":"190","author":"L Nymand","year":"2024","unstructured":"Nymand L, Nielsen ML, Vittrup I, et al. Atopic dermatitis phenotypes based on cluster analysis of the Danish Skin Cohort. Br J Dermatol. 2024;190(2):207\u201315. https:\/\/doi.org\/10.1093\/BJD\/LJAD401.","journal-title":"Br J Dermatol"},{"issue":"9","key":"997_CR4","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/JDV.18345","volume":"36","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I\u2014systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409\u201331. https:\/\/doi.org\/10.1111\/JDV.18345.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"997_CR5","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.jaad.2023.08.103","volume":"90","author":"DMR Davis","year":"2024","unstructured":"Davis DMR, Drucker AM, Alikhan A, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024;90(2):342\u20135. https:\/\/doi.org\/10.1016\/j.jaad.2023.08.103.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"997_CR6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/all.13954","volume":"75","author":"T Bieber","year":"2020","unstructured":"Bieber T. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75(1):54\u201362.","journal-title":"Allergy"},{"issue":"7","key":"997_CR7","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.jid.2018.12.018","volume":"139","author":"LC Tsoi","year":"2019","unstructured":"Tsoi LC, Rodriguez E, Degenhardt F, et al. Atopic dermatitis is an IL-13\u2013dominant disease with greater molecular heterogeneity compared to psoriasis. J Investig Dermatol. 2019;139(7):1480\u20139.","journal-title":"J Investig Dermatol"},{"issue":"1","key":"997_CR8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/DER2.116","volume":"3","author":"B Witkoff","year":"2022","unstructured":"Witkoff B, Logas CM, Glick BP, Rosso JQ. JAK inhibitors in the treatment of atopic dermatitis. Dermatol Rev. 2022;3(1):20\u20138. https:\/\/doi.org\/10.1002\/DER2.116.","journal-title":"Dermatol Rev"},{"issue":"1","key":"997_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/NRRHEUM.2015.167","volume":"12","author":"DM Schwartz","year":"2016","unstructured":"Schwartz DM, Bonelli M, Gadina M, O\u2019Shea JJ. Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12(1):25\u201336. https:\/\/doi.org\/10.1038\/NRRHEUM.2015.167.","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"997_CR10","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1242\/JCS.00963","volume":"117","author":"JS Rawlings","year":"2004","unstructured":"Rawlings JS, Rosler KM, Harrison DA. The JAK\/STAT signaling pathway. J Cell Sci. 2004;117(8):1281\u20133. https:\/\/doi.org\/10.1242\/JCS.00963.","journal-title":"J Cell Sci"},{"issue":"8","key":"997_CR11","doi-asserted-by":"publisher","DOI":"10.1001\/JAMADERMATOL.2020.1406","volume":"156","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):1. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2020.1406.","journal-title":"JAMA Dermatol"},{"key":"997_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/S40257-025-00975-3","author":"AD Irvine","year":"2025","unstructured":"Irvine AD, Prajapati VH, Guttman-Yassky E, et al. Efficacy and safety of upadacitinib in patients with moderate-to-severe atopic dermatitis: phase 3 randomized clinical trial results through 140 weeks. Am J Clin Dermatol. 2025. https:\/\/doi.org\/10.1007\/S40257-025-00975-3.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"997_CR13","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","volume":"90","author":"DMR Davis","year":"2024","unstructured":"Davis DMR, Drucker AM, Alikhan A, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024;90(2):e43\u201356.","journal-title":"J Am Acad Dermatol"},{"issue":"18","key":"997_CR14","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1007\/S40265-021-01638-3","volume":"81","author":"ED Deeks","year":"2021","unstructured":"Deeks ED, Duggan S. Abrocitinib: first approval. Drugs. 2021;81(18):2149. https:\/\/doi.org\/10.1007\/S40265-021-01638-3.","journal-title":"Drugs"},{"key":"997_CR15","unstructured":"Pfizer. Japan\u2019s MHLW approves Pfizer\u2019s CIBINQO\u00ae (abrocitinib) for adults and adolescents with moderate to severe atopic dermatitis . September 30, 2021. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/japans-mhlw-approves-pfizers-cibinqor-abrocitinib-adults. Accessed 15 Sept 2025."},{"issue":"11","key":"997_CR16","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.3390\/HEALTHCARE9111575","volume":"9","author":"G Radi","year":"2021","unstructured":"Radi G, Simonetti O, Rizzetto G, Diotallevi F, Molinelli E, Offidani A. Baricitinib: the first jak inhibitor approved in Europe for the treatment of moderate to severe atopic dermatitis in adult patients. Healthcare. 2021;9(11):1575. https:\/\/doi.org\/10.3390\/HEALTHCARE9111575.","journal-title":"Healthcare"},{"issue":"1","key":"997_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/BJD\/LJAE404","volume":"192","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Bunick CG, Hong HC, et al. Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb\/IV study (Level Up). Br J Dermatol. 2024;192(1):36\u201345. https:\/\/doi.org\/10.1093\/BJD\/LJAE404.","journal-title":"Br J Dermatol"},{"issue":"9","key":"997_CR18","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/JAMADERMATOL.2021.3023","volume":"157","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157(9):1047\u201355. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2021.3023.","journal-title":"JAMA Dermatol"},{"issue":"10348","key":"997_CR19","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","volume":"400","author":"K Reich","year":"2022","unstructured":"Reich K, Thyssen JP, Blauvelt A, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet. 2022;400(10348):273\u201382. https:\/\/doi.org\/10.1016\/S0140-6736(22)01199-0.","journal-title":"Lancet"},{"issue":"4","key":"997_CR20","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/S40257-022-00701-3\/TABLES\/3","volume":"23","author":"SB Elmariah","year":"2022","unstructured":"Elmariah SB, Smith JS, Merola JF. JAK in the [Black] box: a dermatology perspective on systemic jak inhibitor safety. Am J Clin Dermatol. 2022;23(4):427\u201331. https:\/\/doi.org\/10.1007\/S40257-022-00701-3\/TABLES\/3.","journal-title":"Am J Clin Dermatol"},{"key":"997_CR21","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/nejmoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316\u201326. https:\/\/doi.org\/10.1056\/nejmoa2109927.","journal-title":"N Engl J Med"},{"key":"997_CR22","unstructured":"U.S. Food and Drug Administration. Janus kinase (JAK) inhibitors: drug safety communication - FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death. https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/janus-kinase-jak-inhibitors-drug-safety-communication-fda-requires-warnings-about-increased-risk. Accessed 15 Sept 2025."},{"key":"997_CR23","unstructured":"European Medicines Agency. Janus kinase inhibitors (JAKi)\u2014referral. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/janus-kinase-inhibitors-jaki. Accessed 15 Sept 2025."},{"issue":"5","key":"997_CR24","doi-asserted-by":"publisher","first-page":"530","DOI":"10.36849\/JDD.9049","volume":"24","author":"O Alani","year":"2025","unstructured":"Alani O, Wang D, Wahood S, et al. Is Upadacitinib cardioprotective in chronic inflammatory diseases? A review of major adverse cardiovascular events and venous thromboembolism in atopic dermatitis. J Drugs Dermatol. 2025;24(5):530\u20133. https:\/\/doi.org\/10.36849\/JDD.9049.","journal-title":"J Drugs Dermatol"},{"key":"997_CR25","doi-asserted-by":"publisher","DOI":"10.2340\/ACTADV.V104.18638","author":"I Vittrup","year":"2024","unstructured":"Vittrup I, Thein D, Francis Thomsen S, Egeberg A, Thyssen JP. Risk factors that impact treatment with oral Janus kinase inhibitors among adult patients with atopic dermatitis: a nationwide registry study. Acta Derm Venereol. 2024. https:\/\/doi.org\/10.2340\/ACTADV.V104.18638.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"997_CR26","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/J.JAAD.2020.08.051","volume":"84","author":"AS Halling","year":"2021","unstructured":"Halling AS, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;84(1):139\u201347. https:\/\/doi.org\/10.1016\/J.JAAD.2020.08.051.","journal-title":"J Am Acad Dermatol"},{"key":"997_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/S40257-025-00927-X","author":"ATM R\u00f8nnstad","year":"2025","unstructured":"R\u00f8nnstad ATM, Bunick CG, Chovatiya R, et al. Real-world evidence of tralokinumab effectiveness and safety: a systematic review and meta-analysis. Am J Clin Dermatol. 2025. https:\/\/doi.org\/10.1007\/S40257-025-00927-X.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"997_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):1\u201311. https:\/\/doi.org\/10.1186\/S13643-021-01626-4.","journal-title":"Syst Rev"},{"key":"997_CR29","unstructured":"Study Quality Assessment Tools|NHLBI, NIH. https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools. Accessed 22 Nov 2024."},{"issue":"12","key":"997_CR30","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1111\/JDV.19378","volume":"37","author":"JI Olydam","year":"2023","unstructured":"Olydam JI, Schl\u00f6sser AR, Custurone P, Nijsten TEC, Hijnen D. Real-world effectiveness of abrocitinib treatment in patients with difficult-to-treat atopic dermatitis. J Eur Acad Dermatol Venereol. 2023;37(12):2537\u201342. https:\/\/doi.org\/10.1111\/JDV.19378.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"997_CR31","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/J.JAAD.2023.05.077","volume":"89","author":"Z Tong","year":"2023","unstructured":"Tong Z, Zhang Y, Zhou K, et al. An observational study of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab. J Am Acad Dermatol. 2023;89(4):826\u20138. https:\/\/doi.org\/10.1016\/J.JAAD.2023.05.077.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"997_CR32","doi-asserted-by":"publisher","first-page":"E332","DOI":"10.1097\/MJT.0000000000001675","volume":"31","author":"J Bai","year":"2024","unstructured":"Bai J, Su W, Fang H, Qiao J. Efficacy of abrocitinib for the treatment of moderate-to-severe atopic dermatitis in real-world practice in a single center. Am J Ther. 2024;31(3):E332\u20134. https:\/\/doi.org\/10.1097\/MJT.0000000000001675.","journal-title":"Am J Ther"},{"issue":"4","key":"997_CR33","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1007\/S11684-024-1063-9\/METRICS","volume":"18","author":"Y Chen","year":"2024","unstructured":"Chen Y, Cao Q, Peng C, et al. Real-world effectiveness and safety of Janus kinase 1 inhibitors for the treatment of moderate-to-severe atopic dermatitis: a single-center, prospective study in China. Front Med. 2024;18(4):752\u20136. https:\/\/doi.org\/10.1007\/S11684-024-1063-9\/METRICS.","journal-title":"Front Med"},{"issue":"6","key":"997_CR34","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1097\/CM9.0000000000002838","volume":"137","author":"Y Hu","year":"2024","unstructured":"Hu Y, Zhao Y, Li H, et al. Good efficacy and safety profile of abrocitinib in Chinese adult patients with atopic dermatitis: a case series study. Chin Med J (Engl). 2024;137(6):740. https:\/\/doi.org\/10.1097\/CM9.0000000000002838.","journal-title":"Chin Med J (Engl)"},{"key":"997_CR35","doi-asserted-by":"publisher","DOI":"10.2340\/ACTADV.V104.19454","author":"E Kamphuis","year":"2024","unstructured":"Kamphuis E, Boesjes CM, Loman L, et al. Real-world experience of abrocitinib treatment in patients with atopic dermatitis and hand eczema: up to 28-week results from the BioDay Registry. Acta Derm Venereol. 2024. https:\/\/doi.org\/10.2340\/ACTADV.V104.19454.","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"997_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/J.JID.2024.10.170","volume":"144","author":"N Murashkin","year":"2024","unstructured":"Murashkin N, Grabovetskaya J, Fedenko E, Vurdov D. 164 Real-World efficacy of abrocitinib in adult and adolescent patients with atopic dermatitis: data from RE-DERMA registry. J Investig Dermatol. 2024;144(12):S256. https:\/\/doi.org\/10.1016\/J.JID.2024.10.170.","journal-title":"J Investig Dermatol"},{"issue":"6","key":"997_CR37","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/1346-8138.17173","volume":"51","author":"A Uchiyama","year":"2024","unstructured":"Uchiyama A, Kosaka K, Ishikawa M, Inoue Y, Motegi S. Real-world effectiveness and safety of abrocitinib in 12 Japanese patients with atopic dermatitis and transcriptome analysis with peripheral blood. J Dermatol. 2024;51(6):849\u201353. https:\/\/doi.org\/10.1111\/1346-8138.17173.","journal-title":"J Dermatol"},{"key":"997_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.05.081","author":"S Keow","year":"2024","unstructured":"Keow S, Abu-Hilal M. Effectiveness of abrocitinib for the treatment of moderate-to-severe atopic dermatitis in patients switched from dupilumab and\/or tralokinumab: a real-world retrospective study. J Am Acad Dermatol. 2024. https:\/\/doi.org\/10.1016\/j.jaad.2024.05.081.","journal-title":"J Am Acad Dermatol"},{"key":"997_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/IJD.17344","author":"JC Armario-Hita","year":"2024","unstructured":"Armario-Hita JC, Pereyra-Rodriguez JJ, Gonz\u00e1lez-Quesada A, et al. Treatment of atopic dermatitis with abrocitinib in real practice in Spain: efficacy and safety results from a 24-week multicenter study. Int J Dermatol Published online. 2024. https:\/\/doi.org\/10.1111\/IJD.17344.","journal-title":"Int J Dermatol. Published online"},{"issue":"1","key":"997_CR40","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1089\/DERM.2023.0132","volume":"35","author":"D Huang","year":"2024","unstructured":"Huang D, Lu J, Tan F. Improvement of pruritus and efficacy in the early stage of therapy with upadacitinib, abrocitinib, or dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: prospective, cohort, observational study. Dermatitis. 2024;35(1):77\u201383. https:\/\/doi.org\/10.1089\/DERM.2023.0132.","journal-title":"Dermatitis"},{"issue":"4","key":"997_CR41","doi-asserted-by":"publisher","first-page":"304","DOI":"10.35541\/CJD.20210474","volume":"55","author":"L Bo","year":"2022","unstructured":"Bo L, Xiaoting S, Shuanglu L, et al. Efficacy and safety of baricitinib in the treatment of moderate-to-severe atopic dermatitis: a clinical observation. Chin J Dermatol. 2022;55(4):304\u20137. https:\/\/doi.org\/10.35541\/CJD.20210474.","journal-title":"Chin J Dermatol."},{"key":"997_CR42","doi-asserted-by":"publisher","DOI":"10.2340\/ACTADV.V102.3978","author":"CM Boesjes","year":"2022","unstructured":"Boesjes CM, Kamphuis E, Zuithoff NPA, et al. Daily practice experience of baricitinib treatment for patients with difficult-to-treat atopic dermatitis: results from the BioDay Registry. Acta Derm Venereol. 2022. https:\/\/doi.org\/10.2340\/ACTADV.V102.3978.","journal-title":"Acta Derm Venereol"},{"key":"997_CR43","doi-asserted-by":"publisher","DOI":"10.2340\/ACTADV.V102.1088","author":"D Rogner","year":"2022","unstructured":"Rogner D, Biedermann T, Lauffer F. Treatment of atopic dermatitis with baricitinib: first real-life experience. Acta Derm Venereol. 2022. https:\/\/doi.org\/10.2340\/ACTADV.V102.1088.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"997_CR44","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/1346-8138.16350","volume":"49","author":"A Uchiyama","year":"2022","unstructured":"Uchiyama A, Fujiwara C, Inoue Y, ichiroMotegi S. Real-world effectiveness and safety of baricitinib in Japanese patients with atopic dermatitis: a single-center retrospective study. J Dermatol. 2022;49(4):469\u201371. https:\/\/doi.org\/10.1111\/1346-8138.16350.","journal-title":"J Dermatol"},{"issue":"6","key":"997_CR45","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1684\/ejd.2023.4618","volume":"33","author":"A De Greef","year":"2023","unstructured":"De Greef A, Ghislain PD, Baeck M. Prolonged real-life experience with baricitinib in patients with moderate-to-severe atopic dermatitis. Eur J Dermatol. 2023;33(6):707\u20139.","journal-title":"Eur J Dermatol"},{"issue":"7","key":"997_CR46","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/1346-8138.16763","volume":"50","author":"T Hagino","year":"2023","unstructured":"Hagino T, Saeki H, Fujimoto E, Kanda N. Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. J Dermatol. 2023;50(7):869\u201379. https:\/\/doi.org\/10.1111\/1346-8138.16763.","journal-title":"J Dermatol"},{"key":"997_CR47","first-page":"340","volume":"75","author":"N Hong","year":"2023","unstructured":"Hong N, Park SYKH. Baricitinib as a useful treatment for mild-to-moderate atopic dermatitis: a real-world experience. Acta Derm Venereol. 2023;75:340\u20131.","journal-title":"Acta Derm Venereol"},{"issue":"10","key":"997_CR48","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1159\/000530394","volume":"184","author":"B Liu","year":"2023","unstructured":"Liu B, Song X, Liao S, Luan T, Zhao Z. Comparison of efficacy of baricitinib and dupilumab in the treatment of Chinese moderate-to-severe atopic dermatitis: a retrospective study. Int Arch Allergy Immunol. 2023;184(10):966\u201374. https:\/\/doi.org\/10.1159\/000530394.","journal-title":"Int Arch Allergy Immunol"},{"key":"997_CR49","doi-asserted-by":"publisher","DOI":"10.2340\/ACTADV.V103.14153","author":"Z Reguiai","year":"2023","unstructured":"Reguiai Z, Becherel PA, Perrot JL, et al. Impact of baricitinib on patients\u2019 quality of life after one year of treatment for atopic dermatitis in real-world practice: results of the Observatory of Chronic Inflammatory Skin Diseases Registry. Acta Derm Venereol. 2023. https:\/\/doi.org\/10.2340\/ACTADV.V103.14153.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"997_CR50","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/J.JAAD.2022.10.034","volume":"88","author":"J Vanlerberghe","year":"2023","unstructured":"Vanlerberghe J, Dezoteux F, Martin C, et al. Effectiveness and tolerance of Janus kinase inhibitors for the treatment of recalcitrant atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol. 2023;88(4):900\u20134. https:\/\/doi.org\/10.1016\/J.JAAD.2022.10.034.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"997_CR51","doi-asserted-by":"publisher","DOI":"10.1111\/JDV.18804","volume":"37","author":"I Vittrup","year":"2023","unstructured":"Vittrup I, Elberling J, Skov L, et al. Short-term real-world experience with baricitinib treatment in Danish adults with moderate-severe atopic dermatitis. J Eur Acad Dermatol Venereol. 2023;37(4):e543-e546. https:\/\/doi.org\/10.1111\/JDV.18804.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"997_CR52","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/IJD.16908","volume":"63","author":"JH Lim","year":"2024","unstructured":"Lim JH, Kwon SH, Lew BL. Real-world experience of baricitinib in atopic dermatitis: including add-on therapy for patients using dupilumab. Int J Dermatol. 2024;63(2):196\u2013200. https:\/\/doi.org\/10.1111\/IJD.16908.","journal-title":"Int J Dermatol"},{"issue":"1","key":"997_CR53","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/S40261-023-01335-X","volume":"44","author":"E Freitas","year":"2024","unstructured":"Freitas E, Paiva Lopes MJ, Cruz MJ, et al. Real-world effectiveness and safety of baricitinib in patients with atopic dermatitis. Clin Drug Investig. 2024;44(1):87\u201390. https:\/\/doi.org\/10.1007\/S40261-023-01335-X.","journal-title":"Clin Drug Investig"},{"key":"997_CR54","doi-asserted-by":"publisher","DOI":"10.1111\/JDV.19979","author":"S Traidl","year":"2024","unstructured":"Traidl S, Heinrich L, Siegels D, et al. Treatment of moderate-to-severe atopic dermatitis with baricitinib: results from an interim analysis of the TREATgermany registry. J Eur Acad Dermatol Venereol. 2024. https:\/\/doi.org\/10.1111\/JDV.19979.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"997_CR55","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/S40268-022-00396-1","volume":"22","author":"A Chiricozzi","year":"2022","unstructured":"Chiricozzi A, Gori N, Narcisi A, et al. Effectiveness and safety of upadacitinib in the treatment of moderate-severe atopic dermatitis: a multicentric, prospective, real-world, cohort study. Drugs RD. 2022;22(3):245\u201352. https:\/\/doi.org\/10.1007\/S40268-022-00396-1.","journal-title":"Drugs RD"},{"issue":"9","key":"997_CR56","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1111\/JDV.18139","volume":"36","author":"G Dal Bello","year":"2022","unstructured":"Dal Bello G, Schena D, Girolomoni G. Upadacitinib in patients with resistant atopic dermatitis: a retrospective case-series. J Eur Acad Dermatol Venereol. 2022;36(9):1499\u2013500. https:\/\/doi.org\/10.1111\/JDV.18139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"997_CR57","doi-asserted-by":"publisher","DOI":"10.1111\/JDV.18311","volume":"36","author":"G Feraru","year":"2022","unstructured":"Feraru G, Nevet MJ, Samuelov L, et al. Real-life experience of upadacitinib for the treatment of adult patients with moderate-to-severe atopic dermatitis\u2014a case series. J Eur Acad Dermatol Venereol. 2022;36(10):e832-e833. https:\/\/doi.org\/10.1111\/JDV.18311.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"997_CR58","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1111\/1346-8138.16549","volume":"49","author":"T Hagino","year":"2022","unstructured":"Hagino T, Saeki H, Kanda N. The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. J Dermatol. 2022;49(11):1158\u201367. https:\/\/doi.org\/10.1111\/1346-8138.16549.","journal-title":"J Dermatol"},{"issue":"6","key":"997_CR59","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1684\/EJD.2022.4365","volume":"32","author":"K Kosaka","year":"2022","unstructured":"Kosaka K, Uchiyama A, Ishikawa M, Watanabe G, ichiroMotegi S. Real-world effectiveness and safety of upadacitinib in Japanese patients with atopic dermatitis: a two-centre retrospective study. Eur J Dermatol. 2022;32(6):800\u20132. https:\/\/doi.org\/10.1684\/EJD.2022.4365.","journal-title":"Eur J Dermatol"},{"issue":"6S","key":"997_CR60","doi-asserted-by":"publisher","first-page":"S124","DOI":"10.1097\/DER.0000000000000958","volume":"33","author":"JJ Pereyra-Rodriguez","year":"2022","unstructured":"Pereyra-Rodriguez JJ, Herranz P, Figuras-Nart I, et al. Upadacitinib for the treatment of atopic dermatitis in a Spanish cohort-real life: fifty-two-week follow-up results. Dermatitis. 2022;33(6S):S124\u20137. https:\/\/doi.org\/10.1097\/DER.0000000000000958.","journal-title":"Dermatitis"},{"key":"997_CR61","doi-asserted-by":"publisher","DOI":"10.2340\/ACTADV.V103.5243","author":"CM Boesjes","year":"2023","unstructured":"Boesjes CM, Van Der Gang LF, Zuithoff NPA, et al. Effectiveness of upadacitinib in patients with atopic dermatitis including those with inadequate response to dupilumab and\/or baricitinib: results from the BioDay Registry. Acta Derm Venereol. 2023. https:\/\/doi.org\/10.2340\/ACTADV.V103.5243.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"997_CR62","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/COD.14276","volume":"88","author":"E Kamphuis","year":"2023","unstructured":"Kamphuis E, Loman L, Han HL, Romeijn GLE, Politiek K, Schuttelaar MLA. Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: results from the BioDay registry. Contact Dermatitis. 2023;88(5):351\u201362. https:\/\/doi.org\/10.1111\/COD.14276.","journal-title":"Contact Dermatitis"},{"issue":"6","key":"997_CR63","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/S40257-023-00798-0","volume":"24","author":"A Chiricozzi","year":"2023","unstructured":"Chiricozzi A, Ortoncelli M, Schena D, et al. Long-term effectiveness and safety of upadacitinib for atopic dermatitis in a real-world setting: an interim analysis through 48 weeks of observation. Am J Clin Dermatol. 2023;24(6):953\u201361. https:\/\/doi.org\/10.1007\/S40257-023-00798-0.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"997_CR64","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1007\/S12325-023-02490-5","volume":"40","author":"A De Greef","year":"2023","unstructured":"De Greef A, Ghislain PD, de Montjoye L, Baeck M. Real-life effectiveness and tolerance of upadacitinib for severe atopic dermatitis in adolescents and adults. Adv Ther. 2023;40(5):2509\u201314. https:\/\/doi.org\/10.1007\/S12325-023-02490-5.","journal-title":"Adv Ther"},{"issue":"2","key":"997_CR65","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/S13555-022-00882-Z","volume":"13","author":"L Gargiulo","year":"2023","unstructured":"Gargiulo L, Ibba L, Cortese A, et al. Real-Life effectiveness and safety of upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis: a single-center 16-week study. Dermatol Ther Heidelb. 2023;13(2):651\u201360. https:\/\/doi.org\/10.1007\/S13555-022-00882-Z.","journal-title":"Dermatol Ther Heidelb"},{"issue":"6","key":"997_CR66","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/J.JAAD.2023.08.059","volume":"89","author":"JR Georgakopoulos","year":"2023","unstructured":"Georgakopoulos JR, Sheka D, Rankin B, et al. Real-world effectiveness and safety of upadacitinib for the treatment of atopic dermatitis in adult patients switched from dupilumab: a multicenter retrospective study. J Am Acad Dermatol. 2023;89(6):1308\u201311. https:\/\/doi.org\/10.1016\/J.JAAD.2023.08.059.","journal-title":"J Am Acad Dermatol"},{"key":"997_CR67","first-page":"22","volume":"103","author":"TY Han","year":"2023","unstructured":"Han TY, Kook HPS. Real-world experience of efficacy and safety of upadacitinib in patients with atopic dermatitis in Korea. Acta Derm Venereol. 2023;103:22.","journal-title":"Acta Derm Venereol"},{"key":"997_CR68","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2276043","author":"T Hagino","year":"2023","unstructured":"Hagino T, Yoshida M, Hamada R, Saeki H, Fujimoto E, Kanda N. Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan. J Dermatol Treat. 2023. https:\/\/doi.org\/10.1080\/09546634.2023.2276043.","journal-title":"J Dermatol Treat"},{"key":"997_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/JCM12031175","author":"S Kiefer","year":"2023","unstructured":"Kiefer S, K\u00f6nig A, Gerger V, et al. Efficacy and treatment satisfaction of different systemic therapies in children and adolescents with moderate-to-severe atopic dermatitis: a real-world study. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/JCM12031175.","journal-title":"J Clin Med"},{"key":"997_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/J.INTIMP.2023.111193","author":"L Li","year":"2023","unstructured":"Li L, Wu N, Liu T, et al. The efficacy and immunological effects of upadacitinib in the treatment of moderate-to-severe Chinese atopic dermatitis patients. Int Immunopharmacol. 2023. https:\/\/doi.org\/10.1016\/J.INTIMP.2023.111193. (Pt A).","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"997_CR71","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.1111\/AJD.14164","volume":"64","author":"FJ Melgosa Ramos","year":"2023","unstructured":"Melgosa Ramos FJ, Gonz\u00e1lez-Delgado V, Motilla JMS, Marta GP, Mateu Puchades A, Sergio SA. Upadacitinib effectiveness in moderate-to-severe atopic dermatitis: a real-life multicentre and retrospective study. Australas J Dermatol. 2023;64(4):e361\u20134. https:\/\/doi.org\/10.1111\/AJD.14164.","journal-title":"Australas J Dermatol"},{"key":"997_CR72","unstructured":"Mikhaylova V, Mukhina O, Bobrikova E et al. New treatment perspectives with JAK-inhibitors (upadacitinib) for atopic dermatitis: the united experience of two Moscow reference-centers. Allergy Eur J Allergy Clin Immunol. 2023;78(Supplement 111) (pp 406\u20137)."},{"issue":"3","key":"997_CR73","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/CED\/LLAC078","volume":"48","author":"M Napolitano","year":"2023","unstructured":"Napolitano M, Potestio L, Hansel K, et al. Efficacy and safety of upadacitinib in adult patients affected by moderate to severe atopic dermatitis: a 16-week real-life dual-centre experience. Clin Exp Dermatol. 2023;48(3):247\u20139. https:\/\/doi.org\/10.1093\/CED\/LLAC078.","journal-title":"Clin Exp Dermatol"},{"issue":"7","key":"997_CR74","doi-asserted-by":"publisher","first-page":"e901","DOI":"10.1111\/JDV.19011","volume":"37","author":"C Patruno","year":"2023","unstructured":"Patruno C, Fabbrocini G, Potestio L, Genco L, Napolitano M. Real-life efficacy and safety of upadacitinib in adolescents with moderate-to-severe atopic dermatitis unresponsive to dupilumab: a case series. J Eur Acad Dermatol Venereol. 2023;37(7):e901\u20133. https:\/\/doi.org\/10.1111\/JDV.19011.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"997_CR75","doi-asserted-by":"publisher","first-page":"211","DOI":"10.18176\/JIACI.0831","volume":"33","author":"JJ Pereyra-Rodriguez","year":"2023","unstructured":"Pereyra-Rodriguez JJ, Herranz P, Figueras-Nart I, et al. Treatment of severe atopic dermatitis with upadacitinib in clinical practice: short-term efficacy and safety results. J Investig Allergol Clin Immunol. 2023;33(3):211\u20133. https:\/\/doi.org\/10.18176\/JIACI.0831.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"4","key":"997_CR76","doi-asserted-by":"publisher","first-page":"e352","DOI":"10.1111\/AJD.14139","volume":"64","author":"V Tran","year":"2023","unstructured":"Tran V, Ross G. A real-world Australian experience of upadacitinib for the treatment of severe atopic dermatitis. Australas J Dermatol. 2023;64(4):e352\u20136. https:\/\/doi.org\/10.1111\/AJD.14139.","journal-title":"Australas J Dermatol"},{"issue":"9","key":"997_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/J.JID.2023.06.050","volume":"143","author":"S Weidinger","year":"2023","unstructured":"Weidinger S, Schadeck T, Mortazawi D, et al. LB1677 first results from the observational up-tained study on effectiveness and disease control in patients with moderate to severe atopic dermatitis treated with upadacitinib. J Investig Dermatol. 2023;143(9):B11. https:\/\/doi.org\/10.1016\/J.JID.2023.06.050.","journal-title":"J Investig Dermatol"},{"key":"997_CR78","doi-asserted-by":"publisher","DOI":"10.1089\/DERM.2024.0346\/ASSET\/IMAGES\/DERM.2024.0346_FIGURE1.JPG","author":"M Bertello","year":"2024","unstructured":"Bertello M, Cinotti E, Rubegni P, et al. Upadacitinib in moderate-to-severe atopic dermatitis: real-life study of long-term efficacy, safety and correlation between clinical effectiveness and subjective perception of disease. Dermatitis. 2024. https:\/\/doi.org\/10.1089\/DERM.2024.0346\/ASSET\/IMAGES\/DERM.2024.0346_FIGURE1.JPG.","journal-title":"Dermatitis"},{"issue":"2","key":"997_CR79","doi-asserted-by":"publisher","first-page":"e152","DOI":"10.1111\/JDV.19507","volume":"38","author":"L Gargiulo","year":"2024","unstructured":"Gargiulo L, Ibba L, Piscazzi F, et al. Effectiveness and safety of upadacitinib for moderate-to-severe atopic dermatitis in a real-world setting: a 52-week retrospective study. J Eur Acad Dermatol Venereol. 2024;38(2):e152\u20134. https:\/\/doi.org\/10.1111\/JDV.19507.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Supplement_2","key":"997_CR80","doi-asserted-by":"publisher","first-page":"ii7","DOI":"10.1093\/BJD\/LJAD498.009","volume":"190","author":"H Lima","year":"2024","unstructured":"Lima H, Pereyra-Rodriguez JJ, Beecker J, et al. 498\u2014Real-world use and effectiveness of upadacitinib in adults and adolescents with atopic dermatitis: preliminary analysis of the real-world multicountry AD-VISE study. Br J Dermatol. 2024;190(Supplement_2):ii7\u20138. https:\/\/doi.org\/10.1093\/BJD\/LJAD498.009.","journal-title":"Br J Dermatol"},{"key":"997_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/J.AD.2024.08.010","author":"FJ Melgosa-Ramos","year":"2024","unstructured":"Melgosa-Ramos FJ, Vicente Villa A, Betlloch Mas I, Santos-Alarc\u00f3n S. Mid-term safety and efficacy of upadacitinib in adolescents with moderate-to-severe atopic dermatitis: a real-life 34-patient multicenter trial. Actas Dermosifiliogr. 2024. https:\/\/doi.org\/10.1016\/J.AD.2024.08.010.","journal-title":"Actas Dermosifiliogr"},{"issue":"6","key":"997_CR82","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/J.AD.2023.07.026","volume":"115","author":"J Naharro-Rodr\u00edguez","year":"2024","unstructured":"Naharro-Rodr\u00edguez J, Bern\u00e1-Rico E, P\u00e9rez-Bootello FJ, P\u00e9rez-Garc\u00eda B. Real-world experience with upadacitinib in adolescents and adults with refractory atopic dermatitis: a 24-week retrospective study. Actas Dermosifiliogr. 2024;115(6):615\u20137. https:\/\/doi.org\/10.1016\/J.AD.2023.07.026.","journal-title":"Actas Dermosifiliogr"},{"issue":"1","key":"997_CR83","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/S40261-023-01336-W","volume":"44","author":"M Napolitano","year":"2024","unstructured":"Napolitano M, Ferrucci SM, Foggia L, et al. Comparison of long-term effectiveness and safety of upadacitinib for atopic dermatitis between dupilumab-exposed and dupilumab-na\u00efve patients. Clin Drug Investig. 2024;44(1):71\u20137. https:\/\/doi.org\/10.1007\/S40261-023-01336-W.","journal-title":"Clin Drug Investig"},{"key":"997_CR84","doi-asserted-by":"publisher","DOI":"10.3390\/JCM13020553","author":"E Pezzolo","year":"2024","unstructured":"Pezzolo E, Ortoncelli M, Ferrucci SM, et al. Drug survival of upadacitinib and predicting factors of discontinuation in adult patients affected by moderate-to-severe atopic dermatitis: an Italian multicenter analysis. J Clin Med. 2024. https:\/\/doi.org\/10.3390\/JCM13020553.","journal-title":"J Clin Med"},{"issue":"2","key":"997_CR85","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/JDV.19581","volume":"38","author":"AR Schl\u00f6sser","year":"2024","unstructured":"Schl\u00f6sser AR, Boeijink N, Olydam J, Nijsten TEC, Hijnen DJ. Upadacitinib treatment in a real-world difficult-to-treat atopic dermatitis patient cohort. J Eur Acad Dermatol Venereol. 2024;38(2):384\u201392. https:\/\/doi.org\/10.1111\/JDV.19581.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Supplement_2","key":"997_CR86","doi-asserted-by":"publisher","first-page":"ii27","DOI":"10.1093\/BJD\/LJAD498.030","volume":"190","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Gooderham M, Calimlim B, et al. 525 - Real-world effectiveness of upadacitinib in moderate-to-severe atopic dermatitis (AD): results from cross-sectional analyses of the CorEvitas AD Registry. Br J Dermatol. 2024;190(Supplement_2):ii27\u20138. https:\/\/doi.org\/10.1093\/BJD\/LJAD498.030.","journal-title":"Br J Dermatol"},{"key":"997_CR87","doi-asserted-by":"publisher","DOI":"10.1089\/DERM.2024.0097","author":"BD Rankin","year":"2024","unstructured":"Rankin BD, Sood S, Park YJ, et al. Effectiveness and safety of upadacitinib in adolescent and adult patients with atopic dermatitis: an analysis of short-term (week 8\u201320) data from a real-world multicenter retrospective review. Dermatitis. 2024. https:\/\/doi.org\/10.1089\/DERM.2024.0097.","journal-title":"Dermatitis"},{"key":"997_CR88","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2344591","author":"T Hagino","year":"2024","unstructured":"Hagino T, Saeki H, Fujimoto E, Kanda N. Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study. J Dermatolog Treat. 2024. https:\/\/doi.org\/10.1080\/09546634.2024.2344591.","journal-title":"J Dermatolog Treat"},{"key":"997_CR89","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2375102","author":"L Gargiulo","year":"2024","unstructured":"Gargiulo L, Ibba L, Bianco M, et al. Upadacitinib 30\u2009mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study. J Dermatolog Treat. 2024. https:\/\/doi.org\/10.1080\/09546634.2024.2375102.","journal-title":"J Dermatolog Treat"},{"key":"997_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/J.INTIMP.2024.113383","volume":"143","author":"Y Yang","year":"2024","unstructured":"Yang Y, Chen J, Xiong S, et al. Comparative effectiveness of upadacitinib versus dupilumab for moderate-to-severe atopic dermatitis: a retrospective cohort study. Int Immunopharmacol. 2024;143:113383. https:\/\/doi.org\/10.1016\/J.INTIMP.2024.113383.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"997_CR91","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/JDV.19643","volume":"38","author":"AH Musters","year":"2024","unstructured":"Musters AH, van Lookeren FL, van der Gang LF, et al. Real-world reported adverse events related to systemic immunomodulating therapy in patients with atopic dermatitis: results from the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry. J Eur Acad Dermatol Venereol. 2024;38(3):530\u201342. https:\/\/doi.org\/10.1111\/JDV.19643.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"997_CR92","doi-asserted-by":"publisher","DOI":"10.3389\/JCIA.2024.12455","volume":"7","author":"A Watanabe","year":"2024","unstructured":"Watanabe A, Kamata M, Okada Y, et al. Real-world effectiveness and safety of baricitinib including its effect on biomarkers and laboratory data in Japanese adult patients with atopic dermatitis: a single-center retrospective study. J Cutan Immunol Allergy. 2024;7:12455. https:\/\/doi.org\/10.3389\/JCIA.2024.12455.","journal-title":"J Cutan Immunol Allergy"},{"key":"997_CR93","doi-asserted-by":"publisher","DOI":"10.1089\/DERM.2024.0014\/ASSET\/IMAGES\/DERM.2024.0014_FIGURE4.JPG","author":"J Zhu","year":"2024","unstructured":"Zhu J, Wu H, Ye Y, et al. Efficacy, safety, and early relapse after cessation of upadacitinib versus dupilumab in adolescents with moderate-to-severe atopic dermatitis: a real-world study in China. Dermatitis. 2024. https:\/\/doi.org\/10.1089\/DERM.2024.0014\/ASSET\/IMAGES\/DERM.2024.0014_FIGURE4.JPG.","journal-title":"Dermatitis"},{"issue":"10246","key":"997_CR94","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","volume":"396","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(20)30732-7.","journal-title":"Lancet"},{"issue":"10290","key":"997_CR95","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10290):2169\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(21)00589-4.","journal-title":"Lancet"},{"issue":"10290","key":"997_CR96","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","volume":"397","author":"E Guttman-Yassky","year":"2021","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(21)00588-2.","journal-title":"Lancet"},{"issue":"2","key":"997_CR97","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/BJD.18898","volume":"183","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183(2):242\u201355. https:\/\/doi.org\/10.1111\/BJD.18898.","journal-title":"Br J Dermatol"},{"issue":"1","key":"997_CR98","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/J.JAAD.2021.02.028","volume":"85","author":"EL Simpson","year":"2021","unstructured":"Simpson EL, Forman S, Silverberg JI, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis: results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5). J Am Acad Dermatol. 2021;85(1):62\u201370. https:\/\/doi.org\/10.1016\/J.JAAD.2021.02.028.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"997_CR99","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/JAMADERMATOL.2020.3260","volume":"156","author":"K Reich","year":"2020","unstructured":"Reich K, Kabashima K, Peris K, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(12):1333\u201343. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2020.3260.","journal-title":"JAMA Dermatol"},{"key":"997_CR100","doi-asserted-by":"publisher","DOI":"10.1001\/JAMADERMATOL.2024.1677","author":"G Hjort","year":"2024","unstructured":"Hjort G, Schwarz CW, Skov L, Loft N. Clinical characteristics associated with response to biologics in the treatment of psoriasis: a meta-analysis. JAMA Dermatol. 2024. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2024.1677.","journal-title":"JAMA Dermatol"},{"key":"997_CR101","unstructured":"Food and Drug Administration. Summary of product characteristics \u2014Abrocitinib. Published online 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/213871s000lbl.pdf. Accessed 4 July 2025."},{"key":"997_CR102","doi-asserted-by":"publisher","DOI":"10.1093\/BJD\/LJAC140.044","author":"H Li","year":"2023","unstructured":"Li H, Cheng H, Lu Q, et al. 352 Efficacy and safety of abrocitinib in Chinese patients with moderate-to-severe atopic dermatitis: a post-hoc analysis of the JADE REGIMEN phase 3 trial. Br J Dermatol. 2023. https:\/\/doi.org\/10.1093\/BJD\/LJAC140.044.","journal-title":"Br J Dermatol"},{"key":"997_CR103","unstructured":"European Medicines Agency. Summary of product characteristics\u2014Abrocitinib. Published online 2021. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2021\/20211209153790\/anx_153790_en.pdf. Accessed 4 July 2025."},{"issue":"1","key":"997_CR104","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/JDV.19426","volume":"38","author":"S Yoon","year":"2024","unstructured":"Yoon S, Kim K, Shin K, et al. The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol. 2024;38(1):52\u201361. https:\/\/doi.org\/10.1111\/JDV.19426.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"997_CR105","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/J.JACI.2023.08.029","volume":"152","author":"AWL Chu","year":"2023","unstructured":"Chu AWL, Wong MM, Rayner DG, et al. Systemic treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials. J Allergy Clin Immunol. 2023;152(6):1470\u201392. https:\/\/doi.org\/10.1016\/J.JACI.2023.08.029.","journal-title":"J Allergy Clin Immunol"},{"key":"997_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/J.JDIN.2024.09.012","author":"D Isufi","year":"2024","unstructured":"Isufi D, Jensen MB, Loft N, Skov L, Elberling J, Alinaghi F. Risk of infections during treatment with oral Janus kinase inhibitors in randomized placebo-controlled trials: a systematic review and meta-analysis. JAAD Int. 2024. https:\/\/doi.org\/10.1016\/J.JDIN.2024.09.012.","journal-title":"JAAD Int."},{"issue":"4","key":"997_CR107","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/J.JAAD.2022.06.012","volume":"87","author":"P Mendes-Bastos","year":"2022","unstructured":"Mendes-Bastos P, Ladizinski B, Guttman-Yassky E, et al. Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: a post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials. J Am Acad Dermatol. 2022;87(4):784\u201391. https:\/\/doi.org\/10.1016\/J.JAAD.2022.06.012.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"997_CR108","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40257-021-00618-3","volume":"22","author":"EL Simpson","year":"2021","unstructured":"Simpson EL, Silverberg JI, Nosbaum A, et al. Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program. Am J Clin Dermatol. 2021;22(5):693\u2013707.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"997_CR109","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1089\/DERM.2022.0027","volume":"34","author":"A Wollenberg","year":"2023","unstructured":"Wollenberg A, Kircik L, Simpson E, et al. Pooled analysis of baricitinib tolerability in patients with atopic dermatitis in relation to acne, headache, and gastrointestinal events from 8 clinical trials. Dermatitis. 2023;34(4):308\u201314. https:\/\/doi.org\/10.1089\/DERM.2022.0027.","journal-title":"Dermatitis"},{"issue":"9813","key":"997_CR110","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S0140-6736(11)60321-8","volume":"379","author":"HC Williams","year":"2012","unstructured":"Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet. 2012;379(9813):361\u201372. https:\/\/doi.org\/10.1016\/S0140-6736(11)60321-8.","journal-title":"Lancet"},{"issue":"9","key":"997_CR111","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1111\/JDV.18193","volume":"36","author":"T Werfel","year":"2022","unstructured":"Werfel T, Irvine AD, Bangert C, et al. An integrated analysis of herpes virus infections from eight randomized clinical studies of baricitinib in adults with moderate-to-severe atopic dermatitis. J Eur Acad Dermatol Venereol. 2022;36(9):1486\u201396. https:\/\/doi.org\/10.1111\/JDV.18193.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"997_CR112","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/J.JACI.2022.09.023","volume":"151","author":"E Guttman-Yassky","year":"2023","unstructured":"Guttman-Yassky E, Thyssen JP, Silverberg JI, et al. Safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis of phase 3 studies. J Allergy Clin Immunol. 2023;151(1):172\u201381. https:\/\/doi.org\/10.1016\/J.JACI.2022.09.023.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"997_CR113","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/S40257-021-00618-3","volume":"22","author":"EL Simpson","year":"2021","unstructured":"Simpson EL, Silverberg JI, Nosbaum A, et al. Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program. Am J Clin Dermatol. 2021;22(5):693\u2013707. https:\/\/doi.org\/10.1007\/S40257-021-00618-3.","journal-title":"Am J Clin Dermatol"},{"key":"997_CR114","doi-asserted-by":"publisher","DOI":"10.1111\/JDV.20229","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Gooderham M, Katoh N, et al. Combining treat-to-target principles and shared decision-making: international expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis. J Eur Acad Dermatol Venereol. 2024. https:\/\/doi.org\/10.1111\/JDV.20229.","journal-title":"J Eur Acad Dermatol Venereol"}],"updated-by":[{"DOI":"10.1007\/s40257-026-01025-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000}}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00997-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-025-00997-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00997-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T05:48:10Z","timestamp":1778046490000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-025-00997-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":114,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["997"],"URL":"https:\/\/doi.org\/10.1007\/s40257-025-00997-x","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"6 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40257-026-01025-2","URL":"https:\/\/doi.org\/10.1007\/s40257-026-01025-2","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethics committee approval or consent was necessary for this type of study as the study was a systematic review and meta-analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval\/consent to participate\/consent for publication"}},{"value":"Dr. R\u00f8nnstad has received research funding from the Department of Clinical Medicine, Copenhagen University and the Kgl Hofbundtmager Aage Bang Foundation. Mr. Isufi has no conflicts of interest. Prof. Bunick has served as an investigator for AbbVie, Almirall, Apogee, Daiichi Sankyo, LEO Pharma, Ortho Dermatologics, Sun Pharma, Timber, and Palvella; a consultant for AbbVie, Almirall, Alumis, Apogee, Arcutis, Connect BioPharma, Eli Lilly, EPI Health\/Novan, Incyte, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Sanofi-Regeneron, Takeda, Teladoc, and UCB. Prof. Chovatiya has served as an advisor, consultant, speaker and\/or investigator for AbbVie, Acelyrin, Alumis, Amgen, AnaptysBio, Apogee Therapeutics, Arcutis Biotherapeutics Inc., Argenx, Astria Therapeutics Inc., Avalere Health, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celldex CLn Skin Care, Dermavant, Eli Lilly and Company, EMD Serono, Formation Bio, Galderma, Genentech, GSK, Incyte, Johnson & Johnson, Kenvue, LEO Pharma, L\u2019Or\u00e9al, Nektar Therapeutics, Novartis, Opsidio, Pfizer Inc., RAPT, Regeneron, Sanofi, Sitryx, Takeda, TRex Bio, UCB, Zai Lab. Raj Chovatiya is an Editorial Board member of American Journal of Clinical Dermatology. Raj Chovatiya was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Dr. Nielsen has received consultancy honoraria from LEO Pharma. Dr. Alinaghi has no conflicts of interest. Prof. Thomsen has received research support from Janssen, LEO Pharma, Novartis, Sanofi and UCB, and has been a speaker\/consultant for Abbvie, CSL, Eli Lilly, Janssen, Galderma, Incyte, LEO Pharma, Novartis, Pfizer, Sanofi, Symphogen, UCB, and Union Therapeutics. Prof. Vestergaard has been an investigator for AbbVie A\/S, Pierre Fabre Dermo-Cosmetique, Novartis, LEO Pharma, Sanofi, Almirall, Galderma and Pfizer. He has served on advisory boards for Astellas Pharma, Almirall, Sanofi, Abb-vie, Galderma, Leo Pharma and MEDA and has been a speaker for Leo-Pharma, Astellas, MSD, AbbVie, Novartis Almirall, Sanofi and Pfizer. Prof. Egeberg has received research funding from Almirall, Pfizer, Eli Lilly, Novartis, Bristol-Myers Squibb, AbbVie, Janssen Pharmaceuticals, Boehringer Ingelheim, the Danish National Psoriasis Foundation, the Simon Spies Foundation, and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as consultant and\/or speaker from Amgen, AbbVie, Almirall, Leo Pharma, Zuellig Pharma Ltd., Gal\u00e1pagos NV, Sun Pharmaceuticals, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly and Company, Novartis, Union Therapeutics, Galderma, Dermavant, UCB, Mylan, Bristol-Myers Squibb, McNeil Consumer Healthcare, Horizon Therapeutics, Boehringer Ingelheim, and Janssen Pharmaceuticals. He is currently an employee at LEO Pharma. Prof. Thyssen has been an advisor for AbbVie, Almirall, Arena Pharmaceuticals, OM Pharma, Aslan Pharmaceuticals, Union Therapeutics, Eli Lilly & Co, LEO Pharma, Pfizer, Regeneron and Sanofi-Genzyme, a speaker for AbbVie, Almirall, Eli Lilly & Co, LEO Pharma, Pfizer, Regeneron, and Sanofi-Genzyme, and received research grants from Pfizer, Regeneron, and Sanofi-Genzyme. He is currently an employee at LEO Pharma. Dr. Loft has been a paid speaker for Eli Lilly, Janssen Cilag, and Sandoz and received research funding from the LEO Foundation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"R\u00f8nnstad, Isufi, Nielsen and Loft had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Loft, Thyssen, Egeberg and R\u00f8nnstad. Acquisition, analysis and interpretation of data: All authors. Drafting of the manuscript: R\u00f8nnstad, Isufi, Bunik, Chovatiya, Thyssen and Loft. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: Nielsen. Administrative, technical, or material support: None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"All data supporting the findings of this study are available within the paper and its Supplementary Information.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material\/code availability"}}]}}